AstraZeneca PLC (AZN) Quote - XLON | Morningstar

Skip to Content

Is it the right time to buy or sell?

Find out with Morningstar Premium

Is it the right time to buy or sell?

Find out with Morningstar Premium

1-Star Price

PREMIUM

5-Star Price

PREMIUM

Economic Moat

PREMIUM

Capital Allocation

PREMIUM

AstraZeneca’s Continual Focus on Innovative Drug Development Increasingly Sets Up Strong Growth

Sector Director Damien Conover

Damien Conover, CFA Sector Director

Analyst Note

| Damien Conover, CFA | Jan 6, 2022

After a deep dive review of several of AstraZeneca’s current and pipeline products, we have increased our projections for several drugs leading to a fair value estimate increase to $64 from $60. We continue to view the company with a wide moat, supported by a strong pipeline and a relatively secure current portfolio with limited near-term patent losses.

Read Full Analysis

Company Profile

Business Description

A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its revenue.

Contact

1 Francis Crick Avenue, Cambridge Biomedical Campus
Cambridge, CB2 0AA, United Kingdom

T +44 2037495000

www.astrazeneca.com

Sector Healthcare

Industry Drug Manufacturers - General

Most Recent Earnings Sep 30, 2021

Fiscal Year End Dec 31, 2021

Stock Type —

Employees 76,100

Related

Stock Analyst Update

Astra and Oxford Report Strong COVID-19 Vaccine

Astra’s vaccine looks potentially easier to transport with only mild temperature requirements as compared with the other vaccines.

Stock Analyst Update

Drug Pricing Executive Orders Not Likely to Affect FVEs

We don’t expect these actions by President Trump to significantly affect our fair value estimates or moat ratings due to limited details, challenging implementation, and only minor impacts.

European Markets Gain

European Markets Gain; Drug-Makers in Focus

Quarter-End Insights

Makings of a Wide Moat in Diabetes Care

Novel products will allow drug firms to achieve price premiums on diabetes drugs in the U.S. and at least retain level pricing internationally.

European Markets Advance

Quarter-End Insights

An Uneasy Calm for European Markets in 1Q

The markets took a stream of negative news and weak economic growth indicators in stride during the first quarter.

Stock Strategist Industry Reports

The Next Wave of Blockbuster Diabetes Drugs

New diabetes drugs offer blockbuster potential for drug companies.

Stock Strategist Industry Reports

Trends So Far in Big Pharma's Fourth Quarter

We're seeing cost cutting, conservative forecasts, and slow new drug launches.

Stock Strategist Industry Reports

The 2010 Outlook for Big Pharma Stocks

Reform or no reform, the pharmaceutical industry is well-positioned.

Stock Strategist

Which Pharma Pipelines Rank Best?

For the majority of pharmaceutical companies, strong pipelines should offset the approaching patent cliff.

Stock Strategist Industry Reports

Which Pharma Pipelines Rank Best?

For the majority of pharmaceutical companies, strong pipelines should offset the approaching patent cliff.

Stock Strategist Industry Reports

Improved Outlook for Big Pharma Stocks in 2009

While challenges remain, we expect Big Pharma to perform well in 2009.

Transparency is our policy. Learn how it impacts everything we do.

Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.

We’d like to share more about how we work and what drives our day-to-day business.

How we make money

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.

How we use your personal data

How we use your information depends on the product and service that you use and your relationship with us. We may use it to:

Verify your identity, personalize the content you receive, or create and administer your account.
Provide specific products and services to you, such as portfolio management or data aggregation.
Develop and improve features of our offerings.
Gear advertisements and other marketing efforts towards your interests.

To learn more about how we handle and protect your data, visit our privacy center.

How we approach editorial content

Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.

To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.

Read our editorial policy to learn more about our process.